
Claims:

1. Use of a compound of the formula



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the medicament is to be administered with one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA synthesis inhibition, and tyrosine kinase inhibition.

2. The use of claim 1 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

3. The use of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

4. The use of claim 3 wherein the additional chemotherapeutic agent is carboplatin.

5. The use of claim 3 wherein the additional chemotherapeutic agent is bevacizumab.

6. The use of any one of claims 1 to 5 wherein the cancer is an epithelial cancer.

7. The use of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The use of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The use of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The use of any one of claims 1 to 9 wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The use of any one of claims 1 to 10 wherein the compound, or the pharmaceutically acceptable salt thereof, and the chemotherapeutic agent are administered in therapeutically effective amounts.

12. The use of claim 11 wherein the effective amounts range from 1 $\mu g/m^2$ to 500 mg/m^2 of body surface area.

13. The use of claim 11 wherein the effective amounts range from 1 $\mu g/m^2$ to 300 mg/m^2 of body surface area.

14. The use of claim 11 wherein the effective amounts range from 10 μg/kg to 100 μg/kg of patient body weight.

15. The use of any one of claims 1 to 5 wherein the cancer is a platinum-resistant ovarian cancer.


16. The use of any one of claims 1 to 15 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The use of any one of claims 1 to 16 wherein the compound, or the pharmaceutically acceptable salt thereof, is in the form of a reconstitutable lyophilizate.

18. The use of any one of claims 1 to 16 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The use of any one of claims 1 to 18 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are administered at doses lower than their maximum tolerable doses.

20. A kit comprising a compound of the formula



,

or a pharmaceutically acceptable salt thereof, and one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule

assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA synthesis inhibition, and tyrosine kinase inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is carboplatin.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is bevacizumab.

25. The kit of any one of claims 20 to 24 wherein the compound, or the pharmaceutically acceptable salt thereof, and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of any one of claims 20 to 25 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile containers or packages.

27. The kit of any one of claims 20 to 26 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of any one of claims 20 to 27 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of any one of claims 20 to 28 wherein the compound, or the pharmaceutically acceptable salt thereof, is in the form of a reconstitutable lyophilizate.


30. The kit of any one of claims 20 to 28 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

31. The use of any one of claims 1 to 19 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile containers or packages before administration.

32. The use of claim 8 wherein the additional chemotherapeutic agent is topotecan.

Claims

1. Use of a compound of the formula



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the medicament is to be administered with one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, and tyrosine kinase inhibition.

2. The use of claim 1 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

3. The use of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

4. The use of claim 3 wherein the additional chemotherapeutic agent is carboplatin.

5. The use of claim 3 wherein the additional chemotherapeutic agent is bevacizumab.

6. The use of any one of claims 1 to 5 wherein the cancer is an epithelial cancer.

7. The use of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The use of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The use of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The use of any one of claims 1 to 9 wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The use of any one of claims 1 to 10 wherein the compound, or the pharmaceutically acceptable salt thereof, and the chemotherapeutic agent are administered in therapeutically effective amounts.

12. The use of claim 11 wherein the effective amounts range from 1 $\mu g/m^2$ to 500 mg/m^2 of body surface area.

13. The use of claim 11 wherein the effective amounts range from 1 $\mu g/m^2$ to 300 mg/m^2 of body surface area.

14. The use of claim 11 wherein the effective amounts range from 10 μg/kg to 100 μg/kg of patient body weight.

15. The use of any one of claims 1 to 5 wherein the cancer is a platinum-resistant ovarian cancer.


16. The use of any one of claims 1 to 15 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The use of any one of claims 1 to 16 wherein the compound, or the pharmaceutically acceptable salt thereof, is in the form of a reconstitutable lyophilizate.

18. The use of any one of claims 1 to 16 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The use of any one of claims 1 to 18 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are administered at doses lower than their maximum tolerable doses.

20. A kit comprising a compound of the formula



or a pharmaceutically acceptable salt thereof, and one or more additional chemotherapeutic agents having a mode of action selected from the group consisting of angiogenesis inhibition, microtubule assembly inhibition, DNA cross-linking, topoisomerase inhibition, DNA intercalation, DNA synthesis inhibition, and tyrosine kinase inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, topotecan, irinotecan, bevacizumab, erlotinib, lapatinib, and pemetrexed.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of carboplatin and bevacizumab.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is carboplatin.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is bevacizumab.

25. The kit of any one of claims 20 to 24 wherein the compound, or the pharmaceutically acceptable salt thereof, and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of any one of claims 20 to 25 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile containers or packages.

27. The kit of any one of claims 20 to 26 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of any one of claims 20 to 27 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of any one of claims 20 to 28 wherein the compound, or the pharmaceutically acceptable salt thereof, is in the form of a reconstitutable lyophilizate.

30. The kit of any one of claims 20 to 28 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

31. The use of any one of claims 1 to 19 wherein the compound, or the pharmaceutically acceptable salt thereof, and the additional chemotherapeutic agent are in sterile containers or packages before administration.